
Leqembi & Kisunla: Extending Independent Living
A new analysis of the benefits of these Alzheimer’s treatments scores the days and ways patients succeed in living independently.

A new analysis of the benefits of these Alzheimer’s treatments scores the days and ways patients succeed in living independently.

The EMA has announced its schedule for reviewing the Alzheimer’s drug Leqembi (lecanemab) for use in Europe. Meanwhile, the U.S. FDA, which already approved the drug, is moving ahead with a new version that doses Leqembi in a better, more convenient fashion for those taking the drug over the long run.

Learn about 2025’s newly approved or potential Alzheimer’s drugs. These include Leqembi, Kisunla, Remternetug, Semaglutide, Trontinemab and Bepranemab.

Leqembi and Kisunla are the new Alzheimer’s immunotherapies. A loss of brain volume associated with these immunotherapies may be caused by the removal of amyloid plaques, rather than the loss of neurons or brain tissue. A new study sheds light on what’s going on.

Europe originally said Lecanemab (Brand-name Leqembi) was too risky to approve. Now they are recommending marketing it. Why the change of heart?

The European Medicines Agency (EMA) recommended approving Leqembi® (generic lecanemab) for Alzheimer’s. Originally skeptics, learn how the “Clarity AD” trial helped change their mind.

Leqembi is an FDA-Approved Alzheimer’s treatment. Hospital infusions take an hour each. 2025 is looking to see a new 15-second autoinjector version. For some, it should even work at home.

Why are some of the new anti-Alzheimer’s antibodies better than others? With the FDA’s approval of Lecanemab and Donanemab, it’s worth staying on top of this topic’s latest research.

The 2 newest Alzheimer’s drugs, Leqembi (lecanemab) and Kisunla (donanemab) show promise, but many questions remain. Here are the three next ones.

Right now, there are two FDA approved drugs to treat Alzheimer’s itself. Find out why Remternetug may soon get approval as a third, even better treatment.

DEMENTIA GIFT IDEAS: People with Alzheimer’s may lose abilities, but feelings still matter. What once wasn’t much of a gift, may now be a great one. What were nice presents may no longer be right. See these thoughtful suggestions.

Alzheimer’s treatment eligibility may be far larger than previously thought. A major Nature study using blood tests suggests millions more older adults could qualify for treatment than current use reflects. As diagnosis becomes easier, demand for drugs like Leqembi could shift sharply.

NEW STUDY: Beetroot is known for improving blood flow—but that may matter more for dementia than many people realize. See the evidence and and what caregivers should realistically take from it.

It is one of the most beautiful Compensations of this life thatNo man can sincerely try to help anotherWithout helping himself.

What are the early symptoms of Alzheimer’s? When to get a professional evaluation.

SHORT-TERM MEMORY lapses are obvious signs of Alzheimer’s, but other tell-tale signals begin to show much earlier. Learn how to look for semantic impairments, such as simple questions about size.

Three important dementia studies focus on HS-AGING, a type of dementia almost as common as Alzheimer’s in the 85+ group. Yet few people have heard of it. Why? What makes it different?
No spam, only news and updates.


